McLaren Health Care and Karmanos Cancer Institute to Create Largest Cancer Research and Provider Network in Michigan Agreement strengthens access to top cancer care across Michigan McLaren Health Care signed an agreement today with The Barbara Ann Karmanos Cancer Institute in Detroit that will create the largest cancer research and provider network in Michigan and expand access to advanced cancer care in southeast Michigan and communities throughout the state. Under the agreement, Karmanos Cancer Institute, which includes the Karmanos Cancer Center, will join the McLaren Health Care system as its newest member. The union brings together the resources of one of Michigan’s largest healthcare delivery systems with one of the nation’s leading cancer research and treatment centers. “McLaren has worked hard to develop Michigan’s largest network of cancer centers and providers, and in seeking ways to strengthen cancer care across our communities, we looked to the leader - Karmanos,” said Philip A. Incarnati, president and chief executive officer of McLaren Health Care. “The Karmanos Cancer Institute has an outstanding reputation for cancer research, providing advanced therapies and unmatched patient care. This new relationship will transform the way new cancer fighting therapies and treatments reach more patients in communities across Michigan. We believe this will become a national model for the delivery of exceptional patient-centered, high quality, evidence-based and cost efficient cancer care.” The benefits to McLaren’s current cancer programs are many, both in research and treatment enhancements. Through the agreement, the McLaren Cancer Institute will become The Barbara Ann Karmanos Cancer Institute, which is one of only 41 National Cancer Institute designated comprehensive cancer centers in the United States. The McLaren Cancer Institute’s cancer clinical trials program will be merged into a single Karmanos Cancer Institute Clinical Trials Office. Over the next several months, Karmanos Cancer Institute will integrate and further develop its clinical service offerings as well as broaden its depth of academic and research services to complement and strengthen McLaren’s cancer care delivery network throughout Michigan. As a result, patients within the McLaren system will have greater access to the depth and breadth of cancer care services and clinical trials at Karmanos. The network of current McLaren cancer centers throughout the state will continue to operate in their respective service areas, and patients will continue to receive treatment through providers at these cancer centers. Other benefits of the agreement include: ● Improved patient experience for McLaren and Karmanos patients ● Stronger clinical integration ● Enhanced clinical trial accrual with advanced access to novel treatments through Phase I and Phase II trials ● Joint sharing of medical expertise and quality improvements between physicians and cancer researchers ● Opportunity to expand and enhance medical education/research programs ● Capital investment for research, education and patient care ● Ability to develop and pilot new models of cancer care ● Enhanced ability to recruit and retain oncology specialists and researchers ● Stronger operations and management expertise when combined “This agreement with McLaren is tremendous news for Karmanos Cancer Institute, its patients and the thousands of individuals and families impacted by cancer in Michigan,” noted Dr. Gerold Bepler, M.D., Ph.D., president and chief executive officer of Karmanos Cancer Institute. “Karmanos has strived to extend its reach into communities to give even more people a better chance at surviving this disease. McLaren is the right partner to help us achieve this vision. This truly integrated model allows us to impact more cancer patients across Michigan while strengthening our efforts at our main campus in Detroit. This ultimately helps Karmanos achieve its mission of preventing, detecting and eventually eradicating cancer. In short, we’re going to save more lives.” The agreement is expected to be effective within several weeks after the boards of both organizations have reviewed and amended their governing documents. Under the terms of the agreement, McLaren will provide a substantial capital investment over a multi-year period to assist with capital upgrades at Karmanos facilities and to fund clinical trials, basic and translational research programs. Both Karmanos Cancer Institute and Karmanos Cancer Center, which provides clinical care to patients, will retain their names and remain as separate legal entities, maintaining their assets and reporting to their existing respective boards of directors. Dr. Bepler will continue as the president and chief executive officer of Karmanos Cancer Institute. Karmanos physicians, nurses and other health care providers will remain at Karmanos’ Detroit, Farmington Hills and Monroe-based locations. Karmanos Cancer Institute and Karmanos Cancer Center will remain anchored in midtown Detroit, and Karmanos will continue its long-standing relationships with Wayne State University School of Medicine and the Detroit Medical Center. About The Barbara Ann Karmanos Cancer Institute Located in midtown Detroit, the Barbara Ann Karmanos Cancer Institute is a 501(c)3 nonprofit organization and one of 41 National Cancer Institute-designated comprehensive cancer centers in the United States. Its treatment facility is the Barbara Ann Karmanos Cancer Center. Caring for more than 6,000 new patients annually on a budget of $260 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, Karmanos is among the nation’s best cancer centers. Through the commitment of more than1,000 staff, including nearly 300 physicians and researchers on faculty at the Wayne State University School of Medicine, and supported by thousands of volunteer and financial donors, Karmanos strives to prevent, detect and eradicate all forms of cancer. Its long-term partnership with the WSU School of Medicine enhances the collaboration of critical research and academics related to cancer care. Gerold Bepler, M.D., Ph.D., is the Institute’s president and chief executive officer. For more information call 1-800-KARMANOS (1-800-527-6266) or go to karmanos.org.
Posted on: Wed, 30 Oct 2013 19:38:31 +0000
Trending Topics
Recently Viewed Topics
© 2015